New therapeutic strategies are needed to protect neonates, especially premature newborns, against brain injury and associated neurobehavioral deficits. The role of pro-inflammatory cytokines, especially IL-1b, in the pathophysiological pathway leading to neonatal brain damage is increasingly recognized and represents an attractive therapeutic target. We investigated the therapeutic potential of postnatal systemic administration of the interleukin (IL)-1 receptor antagonist (IL-1Ra) in an animal model of perinatal brain injury using the insults most common to human neonates, i.e. prenatal exposure to inflammation and/or postnatal hypoxia-ischaemia (HI). We found that postnatal administration of IL-1Ra preserved motor function and exploratory behavior after either prenatal exposure to inflammatory agent lipopolysaccharide (LPS) or postnatal HI insult. The deleterious effect of combined prenatal LPS and postnatal HI on brain development was also alleviated by administration of IL-1Ra, as seen by the protected neural stem cell population, prevention of myelin loss in the internal capsule, decreased gliosis, and decreased neurobehavioral impairment. This study showed the distinct pattern of functional deficits induced by prenatal inflammation as compared to postnatal HI and the therapeutic potential of IL-1Ra administration against neonatal brain injury. Furthermore, our results highlight the potential for postnatal treatment of prenatal inflammatory stressors.
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Introduction
Perinatal brain injury is one of the leading causes of lifelong disability affecting both motor and cognitive functions (Ferriero, 2004; Nelson, 2003; Volpe, 2009 ). The main causes of such brain injury are perinatal hypoxia-ischaemia (HI) and pathogen-induced inflammation, which are often combined and can have a synergistic effect, mainly through pre-and post-natal release of inflammatory mediators (Boksa, 2010; Bracci and Buonocore, 2003; Ferriero, 2004; Girard et al., 2008; Hagberg et al., 2011; Kapitanović Vidak et al., 2012; Meyer, 2011; Nelson, 2003; Volpe, 2009; Wu et al., 2003) . Premature neonates have heightened vulnerability to brain damage. This specific subpopulation of newborns is growing due to the increased rate of preterm birth (Muglia and Katz, 2010) . Unfortunately treatment options remain very limited, especially in preterm newborns. Therapeutic limitations are mainly due to: (i) the lack of non-invasive and reliable diagnostic markers enabling the detection of placental and fetal insults prenatally, and (ii) uncertainties about drug metabolism and benefit/risk balance of drug administration, to both the pregnant mother and fetus (Kenyon et al., 2008; King et al., 2002; Perlman, 2006; Tegethoff et al., 2009) . In contrast, postnatal treatment is a more clinically attractive option since diagnosis of prenatal inflammation and HI are most often made postnatally due to clinical investigations routinely performed in human neonates.
Human neuropathological studies and experimental animal models of perinatal brain injury revealed that pro-inflammatory cytokines, especially those from the IL-1 system, are implicated in the cascade leading to brain damage occurring at different developmental stages (Allan et al., 2005; Cai et al., 2004; Denes et al., 2011; Girard et al., 2008 Girard et al., , 2010a Hagberg et al., 1996; Kadhim et al., 2006 Kadhim et al., , 2003 Martin et al., 1994) . In addition to their direct neurotoxic effects, cytokine imbalances are also suspected to affect brain development since cytokines play an active role in neurogenesis and synaptogenesis (Deverman and Patterson, 2009; Dziegielewska et al., 2000) .
The objective of this study was thus to determine the neuroprotective potential of postnatal systemic administration of low-dose of IL-1Ra, in a model of brain injury triggered by prenatal
